Page 5 - Johnc Jacobs News Today

2.10.2023 - The highly effective vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavaxs adjuvant is critical to reducing over half a million malaria-related deaths annually.

The R21/Matrix-M malaria vaccine is an easily deployable vaccine that can be manufactured at mass scale and modest cost, enabling as many as hundreds of millions of doses to be supplied to countries...

NVX-CoV2601 vaccine adjuvanted 2023-2024 formula granted EUA for the prevention of COVID-19 in those 12 years of age and older.

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the...

Today the U.S. Centers for Disease Control and Preventions Advisory Committee on Immunization Practices voted in favor of a universal recommendation for the use of 2023-2024 COVID-19...

/PRNewswire/ -- SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that its board...

SK Bioscience, a pharmaceutical affiliate of South Korea’s SK Group, said Wednesday it has acquired a 7 percent stake, or 6.5 million shares, in US biotech firm Novavax in a deal worth some 110 billion won ($83.5 million). The stock deal was inked as a mean of payment for Novavax, which owed SK Bioscience for manufacturing the former's COVID-19 vaccine. On top of the new agreement, the companies also exten...

Second quarter total revenue of $424 million and net income of $58 million Executed new strategic partnering agreement with SK bioscience, including an equity...

SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that its board of directors has decided to make an equity investment in Novavax, a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, securing 6.5 million shares of common stock through a private placement.

GAITHERSBURG - Novavax, Inc. , a global company advancing protein-based vaccines with its novel Matrix-M adjuvant, has been granted full Marketing Authorization by the European Commission in the...